Sylvant (Siltuximab) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The sylvant (siltuximab) market research report is one of a series of new reports that provides sylvant (siltuximab) market statistics, including the sylvant (siltuximab) industry global market size, regional shares, competitors with the sylvant (siltuximab) market share, detailed sylvant (siltuximab) market segments, market trends, and opportunities, and any further data you may need to thrive in the sylvant (siltuximab) industry. This sylvant (siltuximab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to rising adoption of biologic therapies, shifting focus toward precision medicine, increasing prevalence of multicentric castleman disease (MCD), advances in immunology and oncology, favorable reimbursement policies. Major trends in the forecast period include growing demand for biologic therapies, expansion of indications and clinical research, advancement in for castleman disease patients, regulatory approvals and market access, increasing immunotherapy demand.

The increasing prevalence of multicentric Castleman disease (MCD) is expected to significantly drive the growth of the Sylvant (siltuximab) market in the coming years. MCD is a rare disorder characterized by abnormal enlargement of lymph nodes and tissues, often associated with inflammation and immune system dysfunction. The rising incidence of MCD can be attributed to improved diagnostic techniques, greater awareness, and advancements in medical imaging. Sylvant (siltuximab) works by targeting and inhibiting interleukin-6 (IL-6), a cytokine responsible for inflammation and disease progression in MCD. By blocking IL-6, it helps reduce inflammation and control the abnormal growth of lymph nodes and tissues, offering an effective treatment for those affected by MCD. For example, in June 2022, the National Organization for Rare Disorders, a US-based nonprofit, reported that approximately 4,300 to 5,200 new cases of Castleman disease are diagnosed annually in the United States. This increase in the number of MCD cases is contributing to the growth of the Sylvant (siltuximab) market.

The shift toward precision medicine is expected to further propel the growth of the Sylvant (siltuximab) market. Precision medicine is an approach that tailors treatments based on an individual's genetic makeup, lifestyle, and environment. This growing demand is driven by advancements in genetic research, a rise in personalized healthcare, and greater adoption of targeted therapies. Sylvant (siltuximab) targets and blocks IL-6, a cytokine involved in the inflammatory process and disease progression. By specifically addressing elevated IL-6 levels in MCD patients, it provides a more personalized and effective treatment compared to traditional therapies. For instance, in February 2024, the Personalized Medicine Coalition, a US-based healthcare organization, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, a significant increase from the six approved in 2022. This trend toward precision medicine is helping drive the growth of the Sylvant (siltuximab) market.

A notable trend in the Sylvant (siltuximab) market is the growing focus on strategic partnerships aimed at improving patient outcomes and addressing unmet clinical needs, particularly in China. These partnerships involve collaborations between organizations to combine their expertise, resources, and strengths to achieve shared objectives and foster market growth. For example, EUSA Pharma, a UK-based pharmaceutical company, partnered with BeiGene, a biotechnology company in China, to announce that the China National Medical Products Administration (NMPA) had accepted their Biologics License Application (BLA) for Sylvant (siltuximab) for injection. This application seeks approval for the treatment of idiopathic multicentric Castleman disease (iMCD), a rare and severe condition affecting the lymph nodes. Sylvant is already approved in over 40 countries, and its acceptance for review by the NMPA marks a significant step in expanding treatment options for patients suffering from this debilitating disease in China.

The key company operating in the sylvant (siltuximab) market is Recordati Rare Diseases Inc.

North America was the largest region in the sylvant (siltuximab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sylvant (siltuximab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sylvant (siltuximab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Sylvant (siltuximab) is a monoclonal antibody that specifically targets and neutralizes interleukin-6 (IL-6), a cytokine involved in inflammation and immune responses. By inhibiting IL-6, it helps reduce inflammation and regulate immune function, particularly in conditions such as multicentric Castleman's disease (MCD). Sylvant is used to manage symptoms of MCD, improve quality of life, and slow disease progression.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for Sylvant (siltuximab) are multicentric Castleman disease (MCD), HIV-associated multicentric Castleman disease (MCD), and non-Hodgkin lymphoma (NHL). MCD is a rare immune disorder characterized by the overgrowth of lymphoid tissue, and Sylvant treats it by targeting specific proteins to reduce inflammation and enhance outcomes. It is available in several forms, including injections, vials, lyophilized powder, infusion solutions, and prefilled syringes, and is utilized by various end users, such as hospitals, specialty clinics, ambulatory surgical centers (ASCs), and home care settings.

The sylvant (siltuximab) market consists of sales of oral dosage forms, compounded solutions, and intravenous (IV) infusion bags. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.